Aptamer Details

Back to Search Results

HD1-15dA (ID# 8198)

50.9 nM (reported value)
In the presence of different concentrations of aptamers (0–1500 nm), human a-thrombin (2.5 NIH units per mL; CellSystems) and UFH (0.01 UmL1; LiqueminO, Roche) were incubated in assay buffer (1 3 PBS, pH 7.4, 3 mm MgCl2, 1 mg/mL1 BSA) for 5 min at room temperature in a total volume of 100 mL. After incubation, a mixture (100 mL) of the fluorogenic peptide-substrate Z-Gly-Gly-Arg-AMC (100 mm; Bachem, Weil am Rhein, Germany) and AT (0.032 UmL1; KyberninO, CSL Behring, Hattersheim am Main, Germany) in assay buffer was added, and the kinetics of thrombin-mediated substrate hydrolysis were monitored at 37 C by using an Ascent Fluoroscan plate reader (Thermo Fisher Scientific, Langenselbold, Germany). Each experiment was performed in duplicate.
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.

Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.

Müller, J., Wulffen, B., Pötzsch, B., & Mayer, G. (2007). Multidomain Targeting Generates a High-Affinity Thrombin-Inhibiting Bivalent Aptamer. ChemBioChem, 8(18), 2223–2226. doi:10.1002/cbic.200700535

Have your aptamer oligo synthesized ORDER